Summary Metformin has been demonstrated to lower blood glucose in vivo by a mechanism which increases peripheral glucose uptake. Furthermore, the therapeutic concentration of metformin has been estimated to be in the order of 0.01 mmol/1. We investigated the effect of metformin on insulin-stimulated 3-0-methylglucose transport in isolated skeletal muscle obtained from seven patients with non-insulindependent diabetes mellitus (NIDDM) and from eight healthy subjects. Whole body insulin-mediated glucose utilization was decreased by 45 % (p < 0.05) in the diabetic subjects when studied at 8 mmol/1 glucose, compared to the healthy subjects studied at 5 mmol/l glucose. Metformin, at concentrations of 0.1 and 0.01 mmol/1, had no effect on basal or insulin-stimulated (100 pU/ml) glucose transport in muscle strips from either of the groups. However, the two control subjects and three patients with NIDDM which displayed a low rate of insulin-mediated glucose utilization (< 20 pmol. kg -1 9 min-1), as well as in vitro insulin resistance, demonstrated increased insulin-stimulated glucose transport in the presence of metforrain at 0.1 mmol/1 (p < 0.05). In conclusion, the concentration of metformin resulting in a potentiating effect on insulin-stimulated glucose transport in insulinresistant human skeletal muscle is 10-fold higher than the therapeutic concentrations administered to patients with NIDDM. Thus, it is conceivable that the hypoglycaemic effect of metformin in vivo may be due to an accumulation of the drug in the extracellular space of skeletal muscle, or to an effect of the drug distal to the glucose transport step. [Diabetologia (1994) 37:826-832 
insulin resistance, and decreased whole body glucose utilization are common characteristic features of patients with NIDDM and/or obesity [5, 6] . The impairment in whole body glucose utilization demonstrated in NIDDM patients has been partly attributed to the muscular glucose transport step [7, 8] . Among the oral antidiabetic agents typically prescribed to patients with NIDDM, metformin has emerged as an effective blood glucose lowering drug used for the treatment of peripheral insulin resistance [9] . Amelioration of hyperglycaemia by metformin treatment in patients with NIDDM appears to be due to an enhanced insulin-mediated glucose metabolism in peripheral tissues [10] . Although metformin does not augment insulin secretion from the pancreas [11, 12] , a low endogenous production of insulin is required to obtain an optimal Values are presented as mean + SEM. ap < 0.05 vs healthy subjects effect of the drug in vivo [13] . Collectively, these observations suggest that the in vivo effect(s) of metformin may have a direct influence upon insulin action and skeletal muscle glucose uptake in patients with NIDDM.
Previously we have reported that metformin, in a concentration of 0.1mmol/1, normalizes the decreased capacity for insulin-mediated glucose transport in insulin-resistant human skeletal muscle when tested under euglycaemic conditions [14] . Nevertheless, the therapeutic concentration of metformin has been estimated to be in the order of 0.01 mmol/1 [15] , and the majority of patients with NIDDM demonstrate chronic hyperglycaemia. Thus, the aim of the present study was to test the hypothesis that metformin corrects a defect at the level of glucose transport in insulin-resistant skeletal muscle exposed to a hyperglycaemic environment. For this purpose we employed an open muscle biopsy technique [16] to obtain intact skeletal muscle from patients with NIDDM, and from healthy subjects. The viability of this muscle strip preparation for in vitro studies has been demonstrated previously by independent groups [8, 16, 17] .
Subjects and methods
Subject characteristics: The study participants consisted of seven patients with NIDDM and eight healthy subjects. All participants were male, and were matched for age. The clinical and metabolic data of the subjects are presented in Table 1 . All of the NIDDM patients were treated with oral anti-hyperglycaemic agents (sulphonylurea). In addition to the sulphonylurea-treatment, two patients received metformin, and one patient was receiving insulin treatment. No evidence of any other metabolic disturbance was identified in the diabetic patients. None of the healthy subjects received any medication known to affect glucose metabolism, and none of the participants were smokers. All of the participants were studied following a 12-h fast. One healthy subject, and one patient with NIDDM did not participate in the hyperinsulinaemic-euglycaemic clamp investigation. The present investigation was approved by the Ethical Committee of the Karolinska Institute, and informed consent was received from all of the study participants.
Muscle strip preparation and 3-O-methylglucose transport determinations:
We have utilized a muscle biopsy technique to obtain intact human skeletal muscle suitable for in vitro investigations [8] . Following administration of local anaesthesia (mevipakain 5 mg/ml), two large muscle samples (-300 mg/ sample) were excised from the lateral portion of the quadriceps femoris muscle as previously described [16] . The muscle specimens were immediately placed in oxygenated, ice cold KHB [18] supplemented with 5 mmol/1 HEPES, 0.1% BSA (RIA grade), 5 retool/1 pyruvate, 5 mmol/1 glutamate and 4 mmol/1 succinate. From the larger specimen, smaller muscle specimens were dissected free (-18 rag), mounted on plexiglass clamps, as described previously [8] and were subsequently incubated in vitro in KHB media (10 min) in individual glass flasks placed in a shaking waterbath (60 times/min, at 35 ~ The gas phase in the flasks was maintained with 95 % O2/ 5 % CO 2. Thereafter, the muscle strips were transferred to a fresh KHB media containing an addition of insulin, or metformin as described in the figures and tables, and incubated for 2 h. The muscle strips were incubated in a near ambient glucose concentration; 5 mmol/1 glucose for control and 8 retool/1 glucose for diabetic muscle strips. Mannitol was added to the KHB media to maintain a constant osmolarity (40 mmol/1) in the presence of the varying glucose concentrations. Prior to exposure to the glucose analogue, 3-0-methylglucose, the muscle strips were exposed to a glucose free media (10 min) in order to rinse glucose from the extra-cellular space. Thereafter, the muscle specimens were transferred to final incubation media (20 min), whereby 3[HI 3-0-methylglucose (347 p~Ci/ mmol) and 14[C] mannitol (8 ~xCi/mmol) were present at a concentration equal to that of the glucose and mannitol, respectively. Preliminary work from our laboratory indicates that the rate of 3-0-methylglucose transport in the presence of 8 mmol/1 glucose and 100 ~xU/ml insulin remains linear for -35m in (J.R.Zierath and H.Wallberg-Henriksson um published results), thus, no counter transport of 3-0-methylglucose occurred during the 20-min radioactive incubation period. The insulin and metformin concentrations were maintained throughout all incubations. Upon termination of the radioactive incubation, the muscle strips were frozen in liquid nitrogen and processed as described by Wallberg-Henriksson et al. [19] . The 3-0-methylglucose transport measurements are expressed per ml of intra-cellular water.
Hyperinsulinaemic-euglycaemic clamp technique:
Whole body insulin-mediated peripheral glucose utilization was evaluated by the hyper-insulinaemic-euglycaemic clamp technique [20] . Under local anaesthesia, one catheter was inserted in the brachial artery for blood sampling and a second catheter was inserted in a forearm vein for insulin and glucose infusion. After obtaining baseline blood samples, a glucose infusion was initiated (1 mg 9 kg -1 9 min -1) and a bolus insulin dose was administered (24 nmol 9 kg -1 9 min -1 for an inital 2 rain, followed by 12 nmol. kg -1 9 rain -~ for 6 rain). Thereafter, a continuous insulin infusion was given (6 nmol-kg -1 9 min-1). A steady-state plasma glucose concentration was maintained for 100 min (5 x 20 min) at fasting levels (approximately 5 or 8 mmol/1 for healthy subjects or NIDDM patients, respectively) by means of a variable glucose infusion rate. The actual plasma glucose concentration was measured at 5-min intervals by the glucose oxidase method (Beckman Glucose Analyzer II Fullerton, Calif. USA). Blood samples for analysis of whole blood glucose and serum insulin levels during steady-state were taken every 30 min. The mean glucose utilization was determined from the glucose infusion rate during the 100 min (5 x 20 min) steady- Correlation between insulin-mediated whole body glucose utilization and the insulin-stimulated 3-0-methylglucose transport rate above basal in insulin sensitive ( 9 and insulinresistant (o) muscles from patients with NIDDM and healthy subjects r = 0.48, p < 0.1 (equation y = 34.10 x + 14.37). One healthy subject and one diabetic patient are not included in the correlation since no glucose utilization data could be obtained from these subjects D. Galuska et al.: Metformin and insulin action on muscular glucose transport method, Pharmacia, Uppsala, Sweden). HbAI~, as a percentage of total blood haemoglobin, was determined at constant room temperature (23 ~ by using a commercially available kit (BioRad Laboratories, Richmond, Calif., USA). The reference value for HbAlo in our laboratory is less than 5.5 %. Unless specifically stated, all chemicals were obtained from Sigma Chemical Company (St. Louis, Me., USA). The isotopes were purchased from New England Nuclear (Boston, Mass., USA.). Insulin Actrapid 100 IE/ml (human) was a product of Nero Nordisk A/ S (Copenhagen, Denmark) and Metformin was a generous gift from Lipha (Lyon, France).
Statistical analysis
A one-way analysis of variance (ANOVA) was used to assess statistical differences between groups. When the ANOVA resulted in a significant F-value, the difference between the means was identified by the Fisher PLSD post hoc test. Student's unpaired t-test was used when comparisons between two mean values were made. Results are expressed as means _+ SEM.
Results

Whole body insulin-mediated glucose uptake in vivo:
Insulin-mediated glucose utilization was assessed by the hyperinsulinaemic-euglycaemic clamp technique. During the clamp procedure, a steady-state plasma glucose concentration was maintained for 100 rain at a near ambient fasting blood glucose level. The mean level during five 20-rain periods was 4.8 + 0.1 mmol/1 for the healthy subjects and 7.3 + 0.4 retool/1 for the NIDDM patients. Despite a significantly higher steady-state serum insulin level in the NIDDM patients (73.8 + 2.6 pU/ml) compared with that of the healthy subjects (67.0 + 2.4 ~tU/ml) (p < 0.05), the mean glucose infusion rate (glucose utilization) was markedly lower in the NIDDM patients (16.9 _+ 4.3 ~tmol. kg -1 9 min -1) when compared to the healthy subjects (30.7 _+ 4.2 ~mol. kg -1. rain -1) (Fig. 1) . The insulinmediated whole body glucose utilization demonstrated a weak, positive correlation with the insulinstimulated rate of 3-0-methylglucose transport measured at the muscular level in the NIDDM patients and the healthy subjects (R = 0.48, p < 0.1; Fig.2 ), In four of the subjects, insulin-resistance was evident based upon the low rate of in vivo whole body insulinmediated glucose utilization and the diminished response of the skeletal muscle glucose transport process to insulin (Fig. 2) .
state conditions. All values were corrected for the glucose abundance, or loss in the intracellular space.
Assays and chemicals:
The glucose concentration in arterial blood obtained during the clamp was determined by the glucose dehydrogenase method using a glucose reagent kit assay (Merck, Darmstadt, Germany). Serum insulin was determined by a standard radioimmunoassay (Phadeseph Insulin RIA
Effect of metformin on 3-O-methylglucose transport:
The basal rate of 3-0-methylglucose transport, measured in skeletal muscle obtained from the patients with NIDDM and the healthy subjects, was unaltered by metformin (0.1 retool/l) ( Table 2) . Nevertheless, basal 3-0-methylglucose transport was slightly, but not significantly, elevated in the diabetic muscles as a response to the hyperglycaemic environment (8 vs . The open circles denote the subjects which were classified as insulin resistant 5 mmot/1 3-0-methylglucose). Insulin, at a concentration of 100 ~U/ml, did not significantly alter the basal rate of the 3-0-methylglucose transport in the muscle strips obtained from the healthy subjects. The insulinstimulated rate of 3-0-methylglucose transport (100 I~U/ml) measured in the muscle strips obtained from the diabetic patients did not differ from that observed in the muscle specimens obtained from the healthy subjects (Table2). Mefformin at 0.1 or 0.01 mmol/1 did not alter the insulin-stimulated rate of 3-0-methylglucose transport in the skeletal muscle specimens obtained from the NIDDM patients (Table 2).
Individual responses for the effect of rnetformin on insulin-stimulated 3-O-methylglucose transport:
The aim of the present study was to test the hypothesis that mefformin normalizes a defect in cellular glucose metabolism at the level of glucose transport. This hypothesis can only be tested if the study group demonstrates a significant decrease in insulin action on glucose transport. Regardless of whether the subjects were categorized as a healthy control group, (Fig. 3 a) or as a diabetic group (Fig. 3 b) , both groups displayed a wide response of the skeletal muscle glucose transport to insulin. However, when the three NIDDM patients which displayed the lowest in vitro and in vivo response to insulin (Fig. 3) were taken together with the two control subjects with the lowest in vitro response to insulin, these subjects collectively demonstrated a 63 % (p < 0.05) increase in in vitro insulinstimulated glucose transport in isolated skeletal muscle strips following exposure to 0.1 mmol/1 metformin. Conversely, no significant potentiating effect of metformin was noted on insulin-mediated 3-0-methylglucose transport in these skeletal muscle strips following exposure to 0.01 mmol/1 of metformin. No differences between these subjects and the rest of the participants were noted in BMI, or fasting plasma glucose and serum insulin levels.
Discussion
Insulin action on glucose transport is markedly impaired in skeletal muscle obtained from lean [7] and obese [8] patients with NIDDM. This defect appears to be due to an altered distribution or activation of the insulin regulatable glucose transporter, GLUT 4, in muscle cells from lean and moderately obese diabetic patients [21, 22] . The present study was undertaken to test the hypothesis that metformin can correct the defect in insulin action on glucose transport in skeletal muscle obtained from patients with NIDDM. Thus, one would only expect an effect of mefformin in muscles which demonstrate an impairment in the capacity for insulin-stimulated glucose transport. Since only three of the seven patients with NIDDM demonstrated muscular insulin-resistance at the cellular level, it was not surprising that metformin did not alter insulin-action on the muscular glucose transport process in the NIDDM group. Because of the heterogeneity of the in vitro responses to insulin displayed by the participants, the individual data was assessed with respect to the five most insulin-resistant participants (three patients with NIDDM and two control subjects). With this approach, we could confirm our earlier finding of a potentiating effect of metformin on insulin action in insulin-resistant human skeletal muscle [14] . However, the potentiating effect of metformin was only noted when muscle strips were exposed to 0.1 mmol/1 metformin. Based on measurements of circulating levels of metformin measured 2 h after an oral dose (0.5-1.0 g/ day), the therapeutic level of metformin has been estimated to be in the order of 0.01 mmol/1 [15] . In the present study, 0.01 mmol/1 of metformin did not significantly alter insulin-stimulated glucose transport in the insulin-resistant subjects. The blood glucose lowering effect of metformin observed in vivo, has been attributed to a potentiating effect on insulin-mediated glucose utilization, primarily on skeletal muscle [10] . However, if the hypoglycaemic effect of the drug is primarily an effect at the level of glucose transport, an accumulation of metformin is likely to occur in vivo, at the cellular surface.
Our results suggest that the muscular glucose transport step per se may not be the primary site of action for the in vivo effect of metformin at a concentration of 0.01 mmol/1. Our findings are in accordance with those of a recent study by Handberg et al. [23] , which demonstrate that chronic metformin treatment does not normalize the decreased GLUT 4 content in skeletal muscle of obese (fa/fa) Zucker rats. Metformin, at a concentration of 0.06 mmol/1, has been suggested to act at the level of glucose transport in isolated rat adipocytes by potentiating the insulininduced translocation of GLUT 1 and GLUT 4 to the plasma membrane from an intracellular domain [24] . Furthermore, the down-regulation of GLUT 4 at the plasma membrane in connection with insulin treatment, has been demonstrated to be prevented by exposing 24 h insulin-treated rat adipocytes to i mmol/1 metformin [25] . Furthermore, lower concentrations of metformin did not block the down-regulation of cell surface content of GLUT 4 caused by chronic insulin treatment of rat adipocytes [25] . Thus, it appears that the effect of metformin on the cellular glucose transport step is concentration dependent.
There are several alternative explanations for the blood glucose lowering effect of metformin which is observed in the in vivo situation. Patients with NIDDM display alterations in both oxidative and nonoxidative glucose metabolism [26] , thus, it is possible that metformin corrects a defect distal to the glucose transport process. Consequently, metformin might improve the reduced glycogen synthase activity which has been noted in skeletal muscle of NIDDM patients [27] . In soleus muscle obtained from streptozotocin diabetic mice, therapeutic concentrations of metformin have been demonstrated to increase insulin-induced glycogen synthase activity by 30 % [28] . Fur-D. Galuska et al.: Metformin and insulin action on muscular glucose transport thermore, in skeletal muscle of diabetic mice, metforrain has been shown to improve hexokinase activity in the absence of insulin [28] , increase glucose oxidation in response to maximal insulin-stimulating concentrations [28] , and enhance insulin-stimulated glycolysis [29] .
Two of the participants in the present study were treated with metformin in conjunction with sulphonylurea treatment. One of these two patients displayed an in vitro response to insulin which was 78 % above the basal glucose transport rate, and skeletal muscle strips from this particular patient did not respond to any of the two metformin concentrations tested. In contrast, the other patient receiving metformin treatment demonstrated whole body (in vivo) and cellular (in vitro) insulin-resistance. The skeletal muscle strips from this patient demonstrated a response to metformin which paralleled that of the other insulin-resistant subjects. However, since the pretreated degree of insulin resistance in these two subj ects is not known, we cannot rule out the possibility of a chronic effect of metformin treatment on skeletal muscle glucose transport.
We have previously demonstrated that skeletal muscle obtained from patients with NIDDM exhibit a decreased dose-response relationship for insulinstimulated 3-0-methylglucose transport in vitro when incubated in glucose free media [7] . In the present study, when muscle strips from the patients with NIDDM were incubated in 8 mmol/1 glucose, the glucose transport capacity was similar to that of the muscle strips obtained from the healthy subjects, incubated in the presence of 5 mmol/1 glucose. This effect can be attributed to the mass-action of glucose [30, 31] . Potentially, the up-regulated glucose transport capacity demonstrated by the muscle strips from the patients with NIDDM might limit a possible potentiating effect of metformin. However, this interpretation seems unlikely since muscle strips from three of the diabetic patients were incubated in the presence of 8 mmol/1 glucose and did respond to the m vitro exposure of metformin. Thus, our results indicate that the potentiating effect of 0.1 mmol/1 metformin on insulin-stimulated glucose transport at the cellular level is not dependent on the level of glycaemia, but rather on the presence of insulin resistance.
A weak positive, but not significant, correlation between the insulin-induced increase of 3-0-methylglucose transport and the whole body insulin-mediated glucose utilization was observed in the patients with NIDDM and the healthy subjects. Nevertheless, those patients which demonstrated the lowest insulin mediated peripheral glucose utilization rates in vivo also demonstrated a marked insulin resistance in vitro. However, the protocol employed for the hyperinsulinaemic-euglycaemic clamp might not have been sufficient to suppress the endogenous glucose pro-duction in the subjects which displayed the lowest glucose utilization rates. Consequently, the glucose utilization rates reported for these subjects might have 8. been moderately underestimated. The lack of a significant insulin-stimulated increase in the rate of 3-0-methylglucose transport in the skeletal muscle strips 9. from the healthy subjects appears to be a reflection of the ageing process and a progressive development of insulin-resistance. Utilizing the same in vitro techni-10. que, we have observed a 2-3-fold stimulation of 3-0-methylglucose transport in skeletal muscle samples from younger (< 35 years) individuals [16, J. R. Zierath and H.Wallberg-Henriksson unpublished observation].
In conclusion, metformin at a concentration of 0.1 mmol/1 exerts a potentiating effect on insulin-stimulated glucose transport in insulin-resistant skeletal muscle, irrespective of the presence of diabetes. Nevertheless, a therapeutic concentration of metformin, 0.01 mmol/1 [15] , did not significantly alter the capacity for insulin-stimulated glucose transport in the insulin-resistant group. Consequently, the in vivo blood glucose lowering effect of metformin could possibly be explained by an accumulation of metforrain in the muscular extracellular space, or by an effect of the drug at a step distal to that of glucose transport.
